MA32818B1 - Arylpiperazines et leur emploi en tant qu'antagonistes de alpha2c - Google Patents

Arylpiperazines et leur emploi en tant qu'antagonistes de alpha2c

Info

Publication number
MA32818B1
MA32818B1 MA33873A MA33873A MA32818B1 MA 32818 B1 MA32818 B1 MA 32818B1 MA 33873 A MA33873 A MA 33873A MA 33873 A MA33873 A MA 33873A MA 32818 B1 MA32818 B1 MA 32818B1
Authority
MA
Morocco
Prior art keywords
antagonists
arylpiperazine
alpha
alpha2c
activity
Prior art date
Application number
MA33873A
Other languages
Arabic (ar)
English (en)
Inventor
Belle David Din
Patrik Holm
Arto Tolvanen
Gerd Wohlfahrt
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of MA32818B1 publication Critical patent/MA32818B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/201,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D327/00Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LES COMPOSÉS DE FORMULE (I), OÙ X, Z, A, B, D, E, R1-R4 ET M SONT TELS QUE DÉFINIS DANS LES REVENDICATIONS, PRÉSENTENT UNE ACTIVITÉ ANTAGONISTE VIS-À-VIS DE ALPHA2C ET PEUVENT DONC ÊTRE EMPLOYÉS EN TANT QU'ANTAGONISTES DE ALPHA2C.
MA33873A 2008-11-20 2011-05-20 Arylpiperazines et leur emploi en tant qu'antagonistes de alpha2c MA32818B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19335508P 2008-11-20 2008-11-20
PCT/FI2009/000097 WO2010058060A1 (fr) 2008-11-20 2009-11-20 Arylpipérazines et leur emploi en tant qu'antagonistes de alpha2c

Publications (1)

Publication Number Publication Date
MA32818B1 true MA32818B1 (fr) 2011-11-01

Family

ID=41490335

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33873A MA32818B1 (fr) 2008-11-20 2011-05-20 Arylpiperazines et leur emploi en tant qu'antagonistes de alpha2c

Country Status (21)

Country Link
US (1) US20110262352A1 (fr)
EP (1) EP2364303A1 (fr)
JP (1) JP5513515B2 (fr)
KR (1) KR20110086747A (fr)
CN (1) CN102216282A (fr)
AR (1) AR074204A1 (fr)
AU (1) AU2009317117A1 (fr)
BR (1) BRPI0921669A2 (fr)
CA (1) CA2741986A1 (fr)
CO (1) CO6382156A2 (fr)
EA (1) EA201170711A1 (fr)
GE (1) GEP20135959B (fr)
IL (1) IL212571A0 (fr)
MA (1) MA32818B1 (fr)
MX (1) MX2011005367A (fr)
NZ (1) NZ592571A (fr)
TN (1) TN2011000218A1 (fr)
TW (1) TW201024282A (fr)
UA (1) UA105647C2 (fr)
WO (1) WO2010058060A1 (fr)
ZA (1) ZA201103462B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
AU2014364735A1 (en) * 2013-12-19 2016-07-07 Bayer Pharma Aktiengesellschaft Substituted piperidinyl-tetrahydroquinolines
EP3083610A1 (fr) * 2013-12-19 2016-10-26 Bayer Pharma Aktiengesellschaft Utilisation de dérivés de bipipéridinyle substitués comme antagonistes des alpha-2c-adrénorécepteurs
EP3083594A1 (fr) * 2013-12-19 2016-10-26 Bayer Pharma Aktiengesellschaft Utilisation de dérivés de bipipéridinyle substitués comme antagonistes des alpha-2c-adrénorécepteurs
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
TWI704145B (zh) 2015-06-05 2020-09-11 芬蘭商奧利安公司 新醫藥化合物
JP2019519582A (ja) 2016-06-29 2019-07-11 オリオン コーポレーション ベンゾジオキサン誘導体およびその医薬用途
CA3113700A1 (fr) 2018-09-25 2020-04-02 Bayer Aktiengesellschaft Antagonistes de recepteur alpha 2-adrenergiques de sous-type c (alpha-2c) pour le traitement de l'apnee du sommeil
CA3139298A1 (fr) 2019-05-09 2020-11-12 Bayer Aktiengesellschaft Combinaison d'un antagoniste de recepteur a2-adrenergiques de sous-type c (alpha-2c) avec un bloqueur de canal task-1/3 pour le traitement de l'apnee du sommeil
US20220218700A1 (en) * 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
CN110615774B (zh) * 2019-09-19 2022-11-11 安徽中医药大学 具有抗炎活性的苄基哌嗪类化合物、制法及医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2695295A (en) * 1952-12-19 1954-11-23 Mcneilab Inc Unsymmetrical n, n'-substituted ethylenediamine and piperazine compounds
US3362956A (en) 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
JPS5515456A (en) * 1978-07-19 1980-02-02 Morishita Seiyaku Kk 2-substituted-piperazinomethyl-1,4-benzodioxane
US4788290A (en) * 1987-12-11 1988-11-29 American Home Products Corporation Serotonergic pyrazine derivatives
FI20000480A0 (fi) 2000-03-01 2000-03-01 Orion Yhtymae Oyj Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
WO2003029239A1 (fr) 2001-10-04 2003-04-10 Wyeth Derives de chromane et de benzofurane utilises comme ligands 5-hydroxytryptamine-6
IL164203A0 (en) 2002-04-03 2005-12-18 Orion Corp Polycyclic compounds as potent alpah2-adrenoceptorantagonists
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
WO2004067513A1 (fr) 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonistes pour recepteurs alpha-2 adrenergiques
TWI457122B (zh) * 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3-二氫苯並[1,4]戴奧辛-2-基甲基衍生物

Also Published As

Publication number Publication date
BRPI0921669A2 (pt) 2018-06-26
ZA201103462B (en) 2012-01-25
JP5513515B2 (ja) 2014-06-04
CO6382156A2 (es) 2012-02-15
IL212571A0 (en) 2011-06-30
CN102216282A (zh) 2011-10-12
EA201170711A1 (ru) 2012-01-30
EP2364303A1 (fr) 2011-09-14
JP2012509302A (ja) 2012-04-19
KR20110086747A (ko) 2011-07-29
MX2011005367A (es) 2011-06-20
TW201024282A (en) 2010-07-01
US20110262352A1 (en) 2011-10-27
NZ592571A (en) 2013-03-28
WO2010058060A1 (fr) 2010-05-27
AU2009317117A1 (en) 2010-05-27
UA105647C2 (uk) 2014-06-10
AR074204A1 (es) 2010-12-29
CA2741986A1 (fr) 2010-05-27
TN2011000218A1 (en) 2012-12-17
GEP20135959B (en) 2013-11-11

Similar Documents

Publication Publication Date Title
MA32818B1 (fr) Arylpiperazines et leur emploi en tant qu'antagonistes de alpha2c
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
UA107672C2 (en) N-(1,2,5-oxadiazol-3-yl)benzamides and the use thereof as herbicides
MX2007005408A (es) Compuestos de aminoquinazolinas.
MX2009009690A (es) Derivados de tiazolidina como antagonistas del receptor de orexina.
WO2009077471A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant
ATE483707T1 (de) 2-cyclopropylthiazolderivate
ECSP12007067A (es) Derivados de quinazolinona útiles como antagonistas vanilloides
CR20120158A (es) Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso.
PL2069332T3 (pl) Związki azetydynowe jako antagoniści receptorów oreksynowych
BR112013007229A2 (pt) ''composição,mistura e processo''.
MY153915A (en) Organic compounds
MX2010001575A (es) Derivados de 1,2-diamido-etileno como antagonistas de orexina.
GEP20156230B (en) Forms of rifaximin and usage thereof
DE602008000754D1 (de) Tropanverbindungen
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
TW200833324A (en) Sulfonamide derivatives
EA201170132A1 (ru) 5-гетероциклилалкил-3-гидрокси-2-фенилциклопент-2-еноны в качестве гербицидов
MX2009010218A (es) Derivados de aza-piridopirimidinona.
MX2010002341A (es) Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.
RS53586B1 (en) DERIVATION OF DECISION
DE602006009789D1 (de) Acetylenderivate
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
UA109037C2 (uk) Триазолопіридини